natgillin/translations-raw huggingface dataset:
a viral infection in a subject, wherein optionally the viral infection comprises hepatitis C infection; 
Spojevi za uporabu prema zahtjevu 23 gdje virusna infekcija obuhvaća hepatitis C infekciju.
when the effective coefficient flag indicates that at least one non-zero transformation coefficient exists in the current sub residual block, obtains transformation coefficients of the current sub residual block based on a significance map indicating a location of the non-zero transformation coefficient in the current sub residual block and level information of the non-zero transformation coefficient in the current sub residual block obtained from the bitstream; when the effective coefficient flag indicates that the at least one non-zero effective transformation coefficient does not exist in the current sub residual block, determines the transformation coefficients of the current second sub residual blocks as zero; and 
kada zastavica kodiranog bloka označava da rezidualni blok transformacije sadrži barem jedan efektivni koeficijent transformacije koji nije nula, dobivanje koeficijenata transformacije prve jedinice frekvencijskog pojasa na temelju karte značajnosti koja ukazuje na mjesta efektivnih koeficijenata transformacije koji nisu nula koji postoje u prvoj jedinici frekvencijskog pojasa i informacije o razini efektivnih koeficijenata transformacije koji nisu nula koji postoje u prvoj jedinici frekvencijskog pojasa dobivenoj iz toka bitova; provođenje inverzne transformacije na rezidualnom bloku transformacije;
processing circuitry configured to compare said reflected pulse of output ultrasonic vibrations with a previously detected pulse of output ultrasonic vibrations reflected from said distal surface of said wall and received at said proximal surface to detect changes in said surface of said wall, wherein said reflected pulse of output ultrasonic vibrations and said previously detected pulse of output ultrasonic vibrations comprise vibrations reflected from said distal surface of said wall in response to different pulses of input ultrasonic vibrations; and 
širi se kroz navedenu stjenku i reflektira od distalne površine navedene stjenke tako da tvori trenutni impuls izlaza ultrazvučnih vibracija na navedenoj proksimalnoj površini, te navedeni postupak sadrži korake: usporedbe navedenog trenutnog impulsa ultrazvučnih vibracija s prethodno detektiranim impulsom izlaza ultrazvučnih vibracija reflektiranim od navedene distalne površine navedene stjenke i primljenih na navedenoj proksimalnoj površini radi otkrivanja promjena u navedenoj površini navedene stjenke.
Thionine Q A diaminophenothiazine compound as described in any of claims 1 to 19 for use in a method of treatment of mild cognitive impairment (MCI) in a patient suffering therefrom, which method comprises administering an effective amount of said diaminophenothiazine compound. 
Diaminofenotiazinski spoj kako je opisan u bilo kojem od patentnih zahtjeva 1 do 19, naznačen i time, da je za uporabu u postupku liječenja blagog kognitivnog poremećaja (BKP) kod pacijenta koji od njega boluje, koji postupak uključuje primjenu učmkovite količine navedenog diaminofenotiazinskog spoja.
The method of clause 1, wherein the first detector is immobilized to a conjugate region of the surface and wherein the conjugate region does not overlap with the test region of the surface. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je prvi detektor imobiliziran na konjugatnom području površine i gdje se konjugatno područje ne preklapa s ispitrvanim područjem površine.
The transdermal delivery device of item 21, where the matrix comprises a material selected from the group consisting of polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethylacrylate copolymers, ethylenevinyl acetate copolymers, silicones, rubber, rubber-like synthetic homo-, co- or block polymers, polyacrylic esters and the copolymers thereof, polyurethanes, polyisobutylene, chlorinated polyethylene, polyvinylchloride, vinyl chloride-vinyl acetate copolymer, polymethacrylate polymer (hydrogel), polyvinylidene chloride, poly(ethylene terephthalate), ethylene-vinyl alcohol copolymer, ethylene-vinyloxyethanol copolymer, silicones (e.g., silicone copolymers such as polysiloxane-polymethacrylate copolymers), cellulose polymers (e.g., ethyl cellulose, and cellulose esters), polycarbonates, polytetrafluoroethylene and mixtures thereof. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da je sloj koji sadrži lijek matrični sloj, i da matrica poželjno sadrži materijal odabran iz skupine koja se sastoji od polietilena, polipropilena, etilen/propilen kopolimera, etilen/etilakrilat kopolimera, etilenvinil acetatnih kopolimera, silikona, gume, sintetičkih homo-, ko- ili blok polimera sličnih gumi, poliakrilinih estera i njihovih kopolimera, poliuretana, poliizobutilena, kloriranih polietilena, polivinilklorida, vinil klorid-vinil acetat kopolimera, polimera polimetakrilata (hidrogel), poliviniliden klorida, poli(etilen tereftalata), etilen-vinil alkohol kopolimera, etilen-viniloksietanol kopolimera, silikona (npr. silikon kopolimera kao što su polisiloksan-polimetakrilat kopolimera), celuloznih polimera (npr. etil celuloze i estera celuloze), polikarbonata, politetrafluorocetilena i njihovih smjesa. .
The integrated circuit according to one of claims 1-4 wherein the first component carrier is a primary cell and the second component carrier is a secondary cell. 
Komunikacijski postupak u skladu s jednim od zahtjeva 7 do 11, naznačen time što je prvi nosač komponenti primarna stanica, a drugi nosač komponenti je sekundarna stanica.
3, with at least one of the mutations selected from the group consisting of amino acid Q at position 1 being replaced by E, amino acid V at position 11 being replaced by L, amino acid G at position 42 being replaced by K, amino acid S at position 50 being replaced by V, amino acid Y at position 53 being replaced by S, amino acid K at position 58 being replaced by T, amino acid G at position 61 being replaced by A, amino acid S at position 75 being replaced by T, amino acid K at position 76 being replaced by R, amino acid N at position 77 being replaced by S, and amino acid T at position 78 being replaced by N. Such an antibody is preferably characterized as comprising the heavy chain constant region the amino acid sequence shown in SEQ ID NO. 
3, gdje se najmanje jednu od mutacija bira iz skupine koju čine aminokiselina Q na položaju 1, zamijenjena s E, aminokiselina V na položaju 11, zamijenjena s L, aminokiselina G na položaju 42, zamijenjena s K, aminokiselina S na položaju 50, zamijenjena s V, aminokiselina Y na položaju 53, zamijenjena s S, aminokiselina K na položaju 58, zamijenjena s T, aminokiselina G na položaju 61, zamijenjena s A, aminokiselina S na položaju 75, zamijenjena s T, aminokiselina K na položaju 76, zamijenjena s R, aminokiselina N na položaju 77, zamijenjena s S, te aminokiselina T na položaju 78, zamijenjena s N, i/ili gdje varijabilno područje lakog lanca sadrži aminokiselinski slijed prikazan u SEQ ID NO.
The method of items 5 to 7, wherein the trans-(-)-A9-tetrahydrocannabinol composition comprises at least about 98% by weight, preferably at least about 99% by weight and more preferably at least about 99.5% by weight of trans-(-)-A9-tetrahydrocannabinol based on the total amount of cannabinoids. 
Postupak prema zahtjevima 1 do 3, naznačen time da sastav trans-(-)-A*-tetrahidrokanabinola sadrži najmanje oko 98% težinski, poželjno najmanje oko 99% težinski i još poželjnije najmanje oko 99.5% težinski trans-(-)-A*- tetrahidrokanabinola bazirano na ukupnoj količini kanabinoida.
reacting an intermediate of formula (VI) in which W3 represents suitable leaving group with an intermediate of formula (IX) in the presence of a suitable catalyst, a suitable base, a suitable solid base, and a suitable solvent, With R1, R2, R3c and n as defined in claim 1; 
reakcija intermedijera formule (VI) gdje W3 predstavlja prikladnu odlazeću skupinu s intermedijerom formule (IX) u prisutnosti prikladnog katalizatora, prikladne baze, prikladne krute baze i prikladnog otapala, [image] s R1, R2, R3c i n kako su definirani u zahtjevu 1;
substituting X with PLG by reaction of a reagent PLG-H in the presence of a base, to obtain a compound of formula II′ 
(0-3) supstitucija X s PLG pomoću reakcije reagensa PLG-H u prisutnosti baze, kako bi se dobio spoj 15
Nutritional composition according to any one of the preceding claims wherein at least 35 wt.% of the palmitic acid is esterified to the sn-2 position of a triglyceride based on total palmitic acid. 
4. Nutritivni pripravak prema bilo kojem od prethodnih zahtjeva gdje je barem 35 tež.% palmitinske kiseline od ukupne palmitinske kiseline esterificirano na sn-2 položaju triglicerida.
or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof: 
[image] ili njegovi geometrijski izomeri, enantiomeri, diastereomeri, racemati, njihove farmaceutski prihvatljive soli i solvati.
The iron waste can be used alone, or mixed with some other sorbents, to enhance, improve one or more aspects of the performance. Such sorbents may include, but not limited to, sodium sesquicarbonate (Trona), sodium bicarbonate, sodium carbonate, zinc ferrite, zinc copper ferrite, zinc titanate, copper ferrite aluminate, copper aluminate, copper manganese oxide, nickel supported on alumina, zinc oxide, iron oxide, copper, copper (I) oxide, copper (II) oxide, limestone, lime, iron filings, Fe, FeO, Fe2O3, Fe3O4, CaCO3, Ca(OH)2, CaCO3.MgO, silica, alumina, china clay, kaolinite, bauxite, emathlite, attapulgite, coal ash, egg shells, and Ca-montmorillonite. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, ili modificirano zamjensko gorivo u skladu s bilo kojim patentnim zahtjevom 3 do 7, naznačeno time, da su dva ili više sorbensa odabrana iz skupine koju čine: trinatrij hidrogendikarbonat dihidrat (Trona), natrijev bikarbonat, natrijev karbonat, cinkov ferit, cink-bakar ferit, cinkov titanat, bakar-ferit aluminat, bakrov aluminat, bakar-oksid mangan, nikal na glini, cinkov oksid, željezni HR P20170938 T1 oksid, bakar, bakrov (I) oksid, bakrov (II) oksid, vapnenac, vapno, Fe, FeO, Fe,O:3, Fe:04, željezna strugotina, CaCO>s, Ca (OH) 2, CaCOs5 x MgO, silicijev dioksid, aluminijev oksid, kaolin, kaolinit, boksit, ematlit, atapulgit, ugljeni pepel, ljuska jajeta i Ca-montmorilonit.
The method of claim 1 or claim 2, wherein the receiving step comprises receiving a notification from an HLR scanner, the HLR scanner being arranged to detect a location update message received by a Home Location Register (HLR) to which the subscribed device is subscribed, the location update message corresponding to the change in current location of the subscribed device. 
Home Location Register) (111), skraćeno HLR, na koji je pretplatnički uređaj pretplaćen, pri čemu poruka o promjeni lokacije odgovara promjeni trenutne lokacije pretplatničkog uređaja.
While certain preferred embodiments and constructions and arrangements of particular components of the invert arm assembly have been shown and described herein, one of ordinary skill in this art will readily understand that modifications and substitutions can be made without departing from the spirit and scope of the invention as defmed by the appended claims. 
Dok su ovdje prikazane i opisane određene izvedbe i konstrukcijska rješenja pojedinih komponenti sklopa invertirajuće ruke, netko s malo iskustva u ovom području će lako shvatiti da se mogu napraviti modifikacije i izmjene bez da se mijenja duh i područje izuma, kao što je definirano u priloženim zahtjevima.
iii) one or more binders; and 
(11) jedno ili više veziva; i
calculating an average value for the plurality of measured absorbances for the reaction liquid (W) having a standard deviation judged to not exceed the threshold (LT) (ii); and 
(ili) izračunavanje prosječne vrijednosti za mnoštvo izmjerenih apsorbancija za reakcijsku tekućinu (W) koja ima standardnu devijaciju za koju je procijenjeno da ne prelazi prag (LT) (ti); te
If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution. 
Ukoliko se koristi tekući nosač pripravak može biti u obliku sirupa, emulzije, kapsule s mekom želatinom, ili u obliku sterilne tekućine za injiciranje kao stoje to vodena ili ne-vodena tekuća suspenzija ili otopina.
A composition comprising interleukin-2 and sodium dodecyl sulfate, wherein IL-2 and sodium dodecyl sulfate are present in the form of aggregates, and wherein the composition has one or more of the following characteristics: 
Sastav koji se sastoji iz interleukina-2 i natrijevog dodecil sulfata, naznačen time, da su IL-2 i natrijev dodecil sulfat prisutni u obliku agregata, i u čemu sastav ima jednu ili više sljedećih karakteristika:
A genetically modified mouse, comprising a humanization of an endogenous mouse IL-6Ra gene, wherein the humanization comprises a replacement of mouse IL-6Ra ectodomain-encoding sequence with human IL-6Ra ectodomain-encoding sequence at the endogenous mouse IL-6Ra locus, and wherein the humanized IL-6Ra gene is under control of endogenous mouse regulatory elements. 
Genetički modificirani miš, koji sadrži humanizaciju endogenog mišjeg IL-6Ra gena, naznačen time da se humanizacija sastoji od zamjene mišje IL-6Ra sekvence koja kodira ektodomenu sa ljudskom IL-6Ra sekvencom koja kodira ektodomenu na lokusu endogenog miša IL-6Ra, te pri čemu je humanizirani IL-6Ra gen pod kontrolom regulacijskih elemenata endogenog miša.
Apparatus as claimed in any one of the preceding claims, characterised in that it is mounted or mountable to adjustable support means providing a rest for a patient's head. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da je pričvršćen ili se može pričvrstiti na podesive nosače koji tvore naslon za glavu za pacijenta
reducing the composition into granules; 
(v) Sušenje granula;
After cooling to −78° C., the mixture was quenched with ethanol and the ammonia was allowed to evaporate. 
Nakon hlađenja do -78 "C smjesu se ugasi etanolom, te ostavi da otpari amonijak.
The therapeutic hosiery item according to claims 3 or 4, characterized in that the count of the coating yarn or yarns of said elastomer yarn (2a) of said second rows of knitting (2) is comprised between 8.89 and 122.22 dtex. 
Terapeutska čarapa prema zahtjevu 3 ili 4, naznačena time, da se broj prevučenog konca, odnosno konaca spomenutog elastomerog konca (2a) spomenutih parnih redova pletiva (2) nalazi između 8,89 i 122,22 deteksa.
The polypeptide of claim 4, wherein said polypeptide is obtained by tryptic digestion of human sclerostin, preferably wherein said human sclerostin is treated with trypsin to achieve complete trypsin digestion and said polypeptide is isolated by HPLC. 
Polipeptid u skladu patentnim zahtjevom 3 ili 4, naznačen time, da se rečeni ljudski sklerostin tretira s tripsinom, kako bi se postigla potpuna digestija tripsina, a rečeni polipeptid se izolira tekućom kromatografijom visokog učinka (HPLC).
is free of surfactants with the exception of polysorbate 80; and 
ne sadrži surfaktante, s izuzetkom polisorbata 80.
The method of claim 10, wherein the core molecule is streptavidin, and wherein the two or more soluble CD33 fusion proteins are biotinylated. 
Multimerski kompleks prema zahtjevu 10, pri čemu je ključna molekula streptavidin, pri čemu su dva ili više fuzijskih proteina biotinilirani.
raised in pressure by the gear pump 8c, and finally 
- - podigne se tlak pomoću zupčane pumpe 8c; i na kraju
The rasagiline citrate of any one of claims 1-6 or the composition of any one of claims 7-13, for use in treating a human subject afflicted with Parkinson's disease, wherein the human subject optionally suffers from delayed gastric emptying, or the human subject is optionally in a fed state. 
Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-9, naznačen time, da je za uporabu u liječenju čovjeka pogođenog Parkinsonovom bolesti, kod čega čovjek opcionalno pati od odloženog pražnjenja želuca, ili je čovjek opcionalno u stanju sitosti.
Blister inhalers provide better moisture protection of the medicament than capsule inhalers. 
Inhalatori s blister-pakiranjima omogućuju bolju zaštitu lijeka od vlage u usporedbi s inhalatorima na kapsule.
A composite material obtained by the process according to any one of claims 1 to 29, comprising the surface-reacted natural calcium carbonate and a polymeric flocculant as defined in one of the claims 1 to 23 and at least one of the impurities selected from heavy metal impurities, microorganisms, polycyclic compounds, cholesterol and endocrine disrupting compounds. 
Kompozitni materijal dobiven postupkom prema bilo kojem od zahtjeva 1 do 19, koji sadrži površinski-reagirani prirodni kalcij karbonat kao što je definiran u jednom od zahtjeva 1 do 15 i barem jednu od nečistoća izabranih iz nečistoća teških metala, organskih nečistoća, mikroorganizama, policikličnih spojeva, kolesterola 1 spojeva koji izazivaju endokrine poremećaje, te poželjno nadalje sadrži aktivni ugljen.
After 1 hour, the reaction mixture is cooled to 0°C and a solution of 3,4-difluoro-benzenesulfonyl chloride (0.83 mL, 6.27 mmol) in DMF (3 mL) is added. 
Nakon 1 sata, reakcijsku smjesu se ohladi na O*C i doda se otopinu 3,4-difluor-benzensulfoml klorida (0,83 ml, 6,27 mmolova) u DMF-u (3 ml).
For example, the administered dosage of aminoglycoside antibiotic may be divided into two to six unit doses, more preferably three to five unit doses and even more preferably four unit doses. 
Tobramicin za uporabu prema zahtjevu 18, naznačen time, da je jedna doza suhog sastava praškastog aerosola, koja sadrži od 110 do 115 mg tobramicina, podijeljena u tri do pet jediničnih doza, poželjno u četiri jedinične doze.
delumping the extragranular lubricant using a suitable screedmill and blend with granules from step (4); 
uklanjanja grudica iz ekstragranularnog lubrikanta upotrebom sita ili mlina i miješanja sa granulama iz koraka (5);
The ddRNAi agent according to claim 5, wherein at least one of the other effector sequences is a sequence selected from the sequences set forth in SEQ ID NOs: 1 to 8 or 10 to 27. 
Agens za ddRNKi prema patentnom zahtjevu 6, gdje najmanje jedna od drugih efektorskih sekvenci je sekvenca izabrana od sekvenci navedenih u SEQ ID NO: 1 do 8 ili 10 do 27.
Preferably, ultrafiltration is carried out between steps (b) and (c), and/or after step (e). 
Poželjno, ultrafiltracija se provodi između koraka (b) i (c) i/ili nakon koraka (e).
A method for controlling: C-terminal lysine content of an antibody or antigen-binding fragment thereof having a C-terminal lysine content of 20% to 70%; 
Postupak za kontrolu: a) sadržaja C-terminalnog lizina protutijela ili njegovog fragmenta koji veže antigen koji ima sadržaj C- terminalnog lizina od 20% do 70%;
The isolated antibody or antigen binding fragment of claim 1 or 2, which is fully human. 
Izolirano protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1 ili 2, naznačeno time da sadrži izolirano posve ljudsko protutijelo koje
The method of claim 4 wherein the administration route is intradermal, mucosal, intramuscular, subcutaneous, sublingual, rectal, or vaginal. 
Smjesa za upotrebu u metodi prema bilo kojem od patentnih zahtjeva 8-10, naznačena time, što je smjesa namijenjena za primjenu intradermalnim, mukoznim, intramuskularnim, supkutanim, sublingvalnim, rektalnim ili vaginalnim putem.
The method claim 1, wherein the nucleic acid insert comprises a selection cassette adjacent to a first homology arm that hybridizes to a first target sequence, wherein the first homology arm is the 5′ homology arm and the first target sequence is the 5′ target sequence, or wherein the first homology arm is the 3′ homology arm and the first target sequence is the 3′ target sequence, 
Postupak prema zahtjevu 2, naznačen time, da je umetak nukleinska kiselina sadrži kasetu odabira susjedan do prve homologiju rm koji hibridizira s prvim ciljne sekvence, pri čemu je prva ruka homologije 5 'ruka za homologiju, a prva ciljna sekvenca je 5' meta ili gdje je prva ruka homologije 3 'ruka za homologiju, a prva ciljna sekvenca je 3' ciljna sekvenca, pri čemu identifikacija sadrži:
Total number of cells (mill) 
(21) Broj predmeta:
The modified FGF-1 for the use according to claim 1, wherein the ocular disease, disorder or condition of the corneal epithelium is a dry eye syndrome or corneal epithelial damage from corneal surgery or transplantation. 
Modificirani FGF-1 za uporabu u skladu s patentnim zahtjevom 1, naznačen time što je očna bolest, poremećaj ili stanje epitela rožnice sindrom suhog oka ili oštećenje epitela rožnice koji se izvodi iz operacije ili presađivanja rožnice.
3 illustrates a packaging blank according to the invention comprising an incision line comprising a series of perforations forming a partly detachable section 4 located at the periphery of said central area of said first area 3 . The manufacturing of the packaging blank comprises unrolling of a shrink film on a conveyor belt. The shrink film is partly cut beforehand, by means of a patterned roulette, by means of a cutter, or by a laser, in order to delimit a partly detachable packaging section 4 which is localized at the periphery of said central area on the first area 3 . 
Postupak prema zahtjevu 1, naznačen time da je navedeni korak reza korak reza prema putanji koja odgovara liniji reza, koja obuhvaća niz perforacija koje formiraju barem jedan djelomično odvojivi dio ambalažnog pakiranja (4), koji je potpuno odvojiv. Postupak prema zahtjevu 1 ili 2, naznačen time da navedena linija reza na periferiji prve zone (3) obuhvaća dio pukotina smještenih kako bi se olakšalo odvajanje navedenog dijela ambalažnog pakiranja (4).
Usage of the material for surface treatment according to any of the claims 12 to 14 is characterized by the fact that the material is spread by coating and/or spraying and/or dipping and/or smoothing and/or painting. 
Uporaba materijala za obradu površina sukladno bilo kojem od patentnih zahtjeva 12 do 14 je naznačena time da je taj materijal nanesen premazivanjem i/ili prskanjem i/ili potapanjem i/ili uglačavanjem i/ili bojanjem.
at least 65 °C for a period of at least one week, or 
(b) najmanje 65 "C kroz razdoblje od najmanje tjedan dana, ili
and cyclization of the compound of formula (VI) is allowed, thereby obtaining a compound of formula (VII), a tautomer (VIIa), and salts thereof; 
(VI) te je omogućeno cikliziranje spoja formule (VI), čime se dobije spoj formule (VII), njegov tautomer (Villa), te njegove soli
In addition the coated fruit was firmer to the touch and the internal flesh was not translucent and displayed no internal brown spots, which is indicative of loss of shell life vs. the control that was translucent and had brown spots in one half of the samples. 
Pored toga što je obloženo voće bilo čvršće na dodir, unutrašnji mesnati dio nije bio proziran i nije bilo unutrašnjih smeđih HR P20070056 T3 točaka, što ukazuje na gubitak roka upotrebe u odnosu na kontrolu koja je bila prozirna i imala je smeđe točke kod jedne polovine uzoraka.
Rc and Rd together form a 3-7 member, preferably a 5 or 6 member cyclic moiety, preferably a cyclic carbohydrate moiety, wherein the cyclic moiety is unsubstituted or substituted, preferably substituted by at least one functional group suitable for conjugation of a polymeric moiety, more preferably substituted in at least one, preferably two or three, and up to all positions of the cycle by hydroxy, substituted or unsubstituted lower alkyl, lower alkoxy, carboxy, alcoxycarbonyl, amino, lower alkylamino, lower alkylaminocarbonyl and/or oxime group, 
(b) R"iR" zajedno formiraju 3-7 -članu cikličnu grupu, pri čemu je ciklična grupa nesupstituirana ili supstituirana sa najmanje jednom funkcionalnom grupom pogodnom za konjugaciju polimerne grupe, 1 pri čemu su R' i Rž isti ili različiti ostatak i svaki je nezavisno izabran iz grupe koju čine: